Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for ...

in combination with balstilimab (BAL). These findings are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The HCC cohort comprised ...

The data focus on botensilimab (BOT) and balstilimab (BAL), highlighting their potential in treating microsatellite stable (MSS) CRC tumors, which typically do not respond well to existing ...

A cluster of brain tumors among nurses working on the same floor at a Massachusetts hospital is raising eyebrows after an investigation found “no environmental risks” at the facility.

Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab ...